title: MCV as a guide to phlebotomy therapy for hemochromatosis.
abstract: BACKGROUND
  A multitude of recommendations exist for laboratory assays to monitor the pace and endpoints of phlebotomy therapy for hemochromatosis. All of these recommendations rely on an assessment of storage iron to guide treatment, and none have been prospectively evaluated.
  
  
  METHODS
  Nine consecutive patients underwent serial monitoring of Hb, MCV, transferrin saturation, and ferritin during weekly phlebotomy to deplete iron stores (induction therapy) and less frequent sessions to prevent iron reaccumulation (maintenance therapy). Changes in MCV and Hb were used to guide the pace of phlebotomy over a median of 7 years of follow-up.
  
  
  RESULTS
  During induction therapy, the MCV increased transiently because of reticulocytosis and then stabilized for a prolonged period before decreasing more sharply, which reflected iron-limited erythropoiesis. Iron depletion was achieved after a median of 38 phlebotomies and removal of 9.0 g of iron. Maintenance phlebotomy was targeted to maintain the MCV at 5 to 10 percent below prephlebotomy values and the Hb at >13 g per dL. Transferrin saturation fluctuated considerably during treatment, but remained below 35 percent during MCV-guided maintenance therapy. Ferritin values were not useful guides to the pace of phlebotomy. The median maintenance therapy phlebotomy interval was 7.5 weeks (range, 6-16), which corresponded to an average daily iron removal of 35 to 67 microg per kg. Most patients showed evidence of iron reaccumulation at phlebotomy intervals of 8 weeks or more.
  
  
  CONCLUSIONS
  The MCV is an inexpensive, precise, physiologic indicator of erythropoietic iron availability. When used in conjunction with the Hb, it is a clinically useful guide to the pace of phlebotomy therapy for hemochromatosis.
authors.affiliation: Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, and the Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: C D
authors.initials: CD
authors.lastname: Bolan
authors.forename: C
authors.initials: C
authors.lastname: Conry-Cantilena
authors.forename: G
authors.initials: G
authors.lastname: Mason
authors.forename: T A
authors.initials: TA
authors.lastname: Rouault
authors.forename: S F
authors.initials: SF
authors.lastname: Leitman
mesh_terms: D000328:Adult; D000368:Aged; D004909:Erythrocyte Indices; D005260:Female; D006432:Hemochromatosis / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018962:Phlebotomy; D011237:Predictive Value of Tests